XK
EPZM

Xact Kapitalforvaltning’s Epizyme, Inc EPZM Stock Holding History

Xact Kapitalforvaltning’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$282K Buy
18,200
+8,300
+84% +$178K 0.01% 1049
2019
Q4 		$244K Buy
+9,900
New +$147K ﹤0.01% 1322

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Xact Kapitalforvaltning's EPZM Position: Q1 2020 in Review

Xact Kapitalforvaltning increased its Epizyme, Inc (EPZM) stake by 84% in Q1 2020, buying an estimated $178K and bringing the position to 18,200 shares worth $282K. The position accounts for 0.01% of the portfolio, ranked #1049.

Xact Kapitalforvaltning first reported a position in EPZM in Q4 2019 and has held it in 2 quarters since. 143 funds tracked by Wall St. Rank hold EPZM as of Q1 2020.

  • Xact Kapitalforvaltning held 18,200 shares of Epizyme, Inc worth $282K as of Q1 2020.
  • Xact Kapitalforvaltning bought 8,300 Epizyme, Inc shares in Q1 2020, an estimated $178K.
  • Epizyme, Inc made up 0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #1049 holding.
  • Xact Kapitalforvaltning first reported a position in Epizyme, Inc in Q4 2019 and has held it in 2 quarters since.
  • 143 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.